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Abstract
Pre-clinical bone cancer pain models mimicking the human condition are required to respond to clinical realities. Breast or
prostate cancer patients coping with bone metastases experience intractable pain, which affects their quality of life.
Advanced monitoring is thus required to clarify bone cancer pain mechanisms and refine treatments. In our model of rat
femoral mammary carcinoma MRMT-1 cell implantation, pain onset and tumor growth were monitored for 21 days. The
surgical procedure performed without arthrotomy allowed recording of incidental pain in free-moving rats. Along with the
gradual development of mechanical allodynia and hyperalgesia, behavioral signs of ambulatory pain were detected at day
14 by using a dynamic weight-bearing apparatus. Osteopenia was revealed from day 14 concomitantly with disorganization
of the trabecular architecture (mCT). Bone metastases were visualized as early as day 8 by MRI (T1-Gd-DTPA) before pain
detection. PET (Na
18F) co-registration revealed intra-osseous activity, as determined by anatomical superimposition over
MRI in accordance with osteoclastic hyperactivity (TRAP staining). Pain and bone destruction were aggravated with time.
Bone remodeling was accompanied by c-Fos (spinal) and ATF3 (DRG) neuronal activation, sustained by astrocyte (GFAP) and
microglia (Iba1) reactivity in lumbar spinal cord. Our animal model demonstrates the importance of simultaneously
recording pain and tumor progression and will allow us to better characterize therapeutic strategies in the future.
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Introduction
Among cancers with a poor prognosis, those originating from
breast, lung and prostate commonly metastasize to the skeleton
[1,2]. While primary bone cancers are rare, over 70% of people
coping with advanced breast or prostate cancer will develop bone
metastases [3]. The major factor responsible for the decrease in
quality of life in bone metastases-bearing patients is pain [4].
Bone cancer pain originates from nerve compression, ischemia
and release of proinflammatory substances by the tumor and cells
from the bone environment [5]. Thus, lytic cancer cells affect bone
homeostasis through the release of cytokines promoting pathological
resorption by osteoclasts [6,7]. In addition to bone destruction [8],
osteoclasthyperactivitycreatesanacidicenvironmentresponsiblefor
the accommodation of pain [9]. Compensative and anarchic bone
formation by osteoblasts compresses free nerve terminal endings
scattered in the bone marrow, matrix and periosteum [10], leading
to the genesis and maintenance of pain. The association of those
phenomenaproducesauniquemechanicalandneurochemicalonset
that goes beyond the combination of neuropathic and inflammatory
pain [11].
Bone cancer pain’s unique characteristics make it therapeuti-
cally intractable [11]. Indeed, typical approaches including anti-
inflammatory drugs and opiates have limited relief efficiency [12].
Due to its progressive nature, escalating doses are required to
adequately alleviate bone cancer pain [13], leading to side effects
and ultimately to abortive compliance [4,14]. Moreover, mor-
phine was recently proven to accelerate cancer-induced bone loss
in osteolytic cancers [15,16]. Similarly, promising anti-resorptive
bisphosphonate therapies [17,18,19,20,21], shown to slow cancer
progression and indirectly alleviate pain, were shaded by comorbid
osteonecrosis [22]. Bone cancer pain thus remains a concern,
highlighting the need to accentuate our understanding of its
neurobiological mechanisms in order to develop more effective
strategies.
Animal models were elaborated to mimic the human condition
in an attempt to understand bone cancer pain. Mouse models of
calcaneus and humerus cancer [23], or rat models of tibia cancer
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prostatic AT-3.1 [27] cells were developed to characterize local
changes or neural plasticity of spinal structures projecting to the
bone. From a clinical point of view, the femur, however, represents
the most frequently affected long bone [28]. Mouse femoral
models involving intramedullary implantation of fibroblast cancer
cell lines to induce pain are reported (e.g. fibrosarcoma [29,30]).
However, those models are based on mimicking primary bone
cancers. The majority of secondary bone cancers originate from
breast or prostate cancers, known for their bone-metastasizing
properties [31]. Yet, for models involving those types of cells,
induction is either intravenous (leading to multiple site metastases
[32,33]) or follows a surgical procedure in which a patellar
arthrotomia and partial alteration of the knee joint are susceptible
to impaired locomotion, which in turn biases the evaluation of
pain-related behavior. Indeed, invasiveness and surgical proce-
dures need to remain minimal in order to assess breakthrough pain
without interference. This latter pain manifestation is the most
refractory condition to overcome for individuals coping with
chronic cancer pain and among the toughest to evaluate in animal
models.
In addition to pain assessment, the means to detect and monitor
bone pathologies have evolved to incorporate X-ray micro-computed
tomodensitometry (mCT) and bone scintigraphy [34]. Nonetheless,
preventive determination of tumor nesting and progression has the
potential to improve analgesic posologies and to limit bone
remodeling. Advanced non-invasive and low radiation medical
imaging,suchaspositronemissiontomography(PET)andmagnetic
resonance imaging (MRI) or the combination of both, would be
desirable to enable efficient and repeated exams for accurate and
rigorous analgesic therapy adjustments [35].
The rat remains the most studied species in pain paradigms
[36]. We therefore selected a rat mammary carcinoma cell line for
its spontaneously metastasizing and transplantable properties. The
capability of MRMT-1 to metastasize to remote organs is intrinsic
to those syngeneic cells [37]. In the present study, we describe an
intervention in the Sprague-Dawley rat femur to implant breast
tumor cells using a light surgical procedure in an effort to mimic
clinical pain. We utilized a combination of innovative behavioral
and medical imaging approaches, supported by immunohisto-
chemical and pathological observations, to characterize the model.
The study aims at improving clinical relevance with regard to the
model and tools used to screen new lead compounds, in order to
characterize bone tumor progression as well as to elucidate the
mechanisms underlying the genesis and maintenance of bone
cancer pain.
Methods
Cell culture
Mammary rat metastasis tumor (MRMT-1) cells (carcinoma)
were kindly provided by the Cell Resource Center for Biomedical
Research Institute of Development, Aging and Cancer (Tohoku
University 4-1, Seiryo, Aoba-ku, Sendai, Japan) and harvested in
RPMI 1640 medium (Gibco, Montreal, Quebec, Canada) supple-
mented with 10% fetal bovine serum (heat-inactivated) and 2%
penicillin/streptavidin (Gibco, Montreal, Qc, Canada). Cells were
detached by brief exposure to 0.25% w/v trypsin-EDTA (Gibco,
Montreal, Qc, Canada) and prepared for injections. Briefly, cells
were pelleted by centrifugation (3 min. at 2006g), rinsed with 1 ml
of Hank’s balanced salt solution exempt of calcium, magnesium or
phenol (HBSS; Gibco, Montreal, Qc, Canada) and further
centrifuged in the same conditions. The pellet was re-suspended
in 1 ml of HBSS, and cells were counted with a hemocytometer.
Cells were diluted to achieve a final concentration for injection of
30000 cells in 20 ml and maintained on ice prior to surgery.
Animals
Adult male Sprague-Dawley rats (200–225 g; Charles River
Laboratories, St.-Constant, Quebec, Canada) were maintainedon a
12 h light/dark cycle with access to food and water ad libitum.
Animal-related procedures were approved by the Ethical Commit-
tee for Animal Care and Experimentation of the Universite ´d e
Sherbrooke and carried out according to the regulations of the
Canadian Council on Animal Care (CCAC). Rats were acclima-
tized for4 daystotheanimalfacilityandfor2 days to manipulations
and devices prior to behavioral studies. Note that animals tested for
pain and used for immunohistochemical analyses were different
from those being imaged by MRI or MRI-PET, since prolonged
anesthesia can affect behavioral responses.
Surgery
After complete anesthesia with 5% isoflurane (Abbott Labora-
tories, Montreal, Qc, Canada), rats were laid in the supine position
and their right paws were shaved and disinfected with 70% v/v
ethanol. Anesthesia was maintained with 2.5% isoflurane and the
rat eyes were protected with an ophthalmic liquid gel (Tear-gel,
Novartis, Mississauga, ON). A minimal skin incision (8–10 mm)
exposed the quadriceps femoris. The vastus lateralis was incised (5–
8 mm in length) to expose the femoral epicondyle, while the
patellar ligament remained untouched and minimal damage was
inflicted to the surrounding muscle and blood vessels. Using a 0.8
A stereotaxic drill (Foredom, Bethel, CT, USA) connected to a
1.75 mm carbide steel burr (Stoelting Co., WoodDale, IL, USA), a
small and superficial cavity was burred between the medial
epicondyle and the adductor tubercle (approximately 1 mm in
depth). In that cavity, a 25-gauge needle was inserted at a 45u
angle, allowing it to reach the intramedullary canal of the femur.
The needle was substituted with a blunt-end 25-gauge needle
connected to a 50 ml Hamilton syringe containing 20 ml of the cell
suspension (cancer group) or of HBSS (sham group). The syringe
was left in place for 1 min to allow cell dispersion in the bone
marrow. The needle was then removed and the cavity was sealed
with dental amalgam (Prodigy A3, Kerr, Orange, CA) and
polymerized with a curing light (QHL75, Dentsply, Milford, DE).
The site was thoroughly washed with sterile deionized water. The
muscle and the conjunctive tissue were closed with a discontinuous
suture made with synthetic absorbable sutures (Monocryl, Ethicon,
Sommerville, NJ), and the skin was closed with a continuous suture
from non-absorbable surgical suture (Prolene, Ethicon, Sommer-
ville, NJ). The wound was finally washed with 3% v/v peroxide
and sprayed with a bitter solution (Aventix Animal health,
Flamborough, ON).
Behavioral studies
Mechanical allodynia was assessed using a dynamic plantar
esthesiometer (Ugo Basile, Stoelting, IL, USA), an automated
version of the von Frey hair. Animals were placed in enclosures on
an elevated wire mesh and responses to punctate mechanical
stimulation were assessed using the esthesiometer. A straight metal
filament (0.5 mm diameter) was orientated beneath the pad until it
touched the plantar surface of the hind paw and began to exert an
upward force. The force required to elicit a withdrawal response
was measured in grams and automatically registered when the paw
was withdrawn or the preset cut-off was reached (50 g). Five values
were taken alternately on both ipsilateral (operated side) and
contralateral hind paws at intervals of 15 s.
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analgesiameter (Ugo Basile, Stoelting, IL, USA) that applies a
linearly increasing pressure (16 g/s) via an acrylic stylus. The
stylus was placed over the medial dorsum of the hind paw,
between the 1st and 2nd tarsometatarsal joints and the mean of
four consecutive measures beginning with the left or right hind
paw, alternately, was recorded as the withdrawal threshold in
grams. The cut-off was set to 200 g. Comparison for each testing
day was performed by subtracting the ipsilateral weight (g) from
the contralateral weight value (g) to determine the paw withdrawal
threshold (PWT) difference.
Static weight bearing was measured using the Incapacitance Meter
(IITC Life Science, Woodland Hills, CA, USA). The animal was
positioned with the hind limbs at rest on the two weight-averaging
platform pads. The unit recorded the average weight put on each
pad over a 2 s period. The measurement was repeated 3 times.
The results obtained with the incapacitance meter were used as a
control for a second weight-bearing test, the Dynamic Weight
Bearing test (Bioseb, Boulogne, France). The device consisted of a
bottomless Plexiglas enclosure (25625624 cm
3) and a sensor
(1936 single captors). The sensor was placed on the floor of the
enclosure, covering its entire surface. The rat was allowed to move
freely within the apparatus for 5 min and the weight-bearing
information was transmitted live to a laptop computer via an USB
interface. The raw data were analyzed with DWB 1.1.0.6 software
(Bioseb). A paw was detected when one captor recorded a weight
of at least 4 g and a minimum of 2 adjacent captors recorded a
weight of at least 1 g. The paw had to be stable for a minimum of
0.5 s to be included. Using a synchronized video-recording of the
test and the scaled map of the detected zones, each presumed paw
was validated by an observer and identified as a left or right and
fore or hind paw. Other zones detected, representing the tail or
another body part, were also included in the analysis.
The effect of subcutaneous morphine was evaluated on days 11, 14, 18
and 21 in our model. Morphine-sulphate stock solution (50 mg/ml)
was diluted in sterile saline to achieve injection concentration
(3 mg/ml). Rats were than injected s.c. with 3 mg/kg (1 ml/g) and
returned to their cage. Behavioral tests were performed 30 minutes
after the injection as described earlier.
Immunohistochemistry
Rats were deeply anaesthetized with 5% isoflurane and
transcardially perfused with 4% paraformaldehyde (PFA) in
phosphate buffer (0.1 M, pH 7.4). The spinal cord and dorsal root
ganglia (DRG) were post-fixed for 30 min in 4% paraformaldehyde
and then transferred to 30% sucrose (48 h) for cryoprotection.
Serial frozen spinal cord sections, 35 mm thick, were cut using a
sliding microtome, collected in PBS and processed as free-floating
sections. Frozen DRG were embedded in OCT Tissue-Tek, cut on
a cryostat at a thickness of 12 mm, collected and processed on slides.
Tissue sections were incubated for 60 min at room temperature
in a blocking solution of 5% normal goat serum in PBS with 0.5%
Triton X-100 and 2% albumin and then incubated for 30 min in
0.1 M glycine solution to reduce autofluorescence. The sections
were then incubated with the primary antiserum overnight at 4uC.
Spinal cord sections were immunostained with antibodies against
markers of microglia, ionized calcium binding adaptor molecule
1 (Iba1, polyclonal antibody rabbit anti-Iba1, 1:1000, Wako,
Richmond, VA, USA), astrocytes, glial fibrillary acidic protein
(GFAP, monoclonal clone GA5 mouse anti-GFAP, 1:500, Sigma,
Oakville, Ontario, Canada) and c-Fos protein (c-Fos, polyclonal
rabbit anti-Fos, 1:20 000, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) and in DRG against activating transcription
factor 3 (ATF-3 (C-19), polyclonal rabbit anti-ATF-3, 1:500, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA). After incuba-
tion, tissue sections were washed two times for 10 min in PBS and
incubated in the secondary antibody solution for 2 h at room
temperature. Secondary antibodies conjugated to fluorescent
markers Alexa FluorH 488 and Alexa Fluor 647H were used at
1:500 (Invitrogen Molecular Probes, Eugene, OR, USA). Sections
were then mounted with Aquamount. The absence of cross-
reactivity among the secondary antibodies was verified by omitting
primary antibody during the overnight incubation.
Fos protein and ATF-3 factor were also detected by immuno-
histochemistry, using the avidin-biotin-peroxidase method. The
DRG slides and spinal cord sections were treated with 0.5%
hydrogen peroxide for 30 min to inhibit endogenous peroxidase
activity and incubated for 30 min in a blocking solution of 5%
normal goat serum, 2% albumin, and 0.5% Triton X-100 in PBS.
Thesections were then incubated overnightat 4uC inthe primary c-
Fos (spinal cord) and ATF-3 (DRG) antibodies, which were diluted
in 1% NGS with 0.1% Triton X-100. After incubation, the sections
were rinsed and blocked with 3% NGS for 15 min and incubated
for 2 h in the secondary antibody, biotinylated goat anti-rabbit IgG
(goat anti-rabbit H+L, 1:500, Vector Laboratories, Burlingame,
CA, USA),followed bystreptavidin-horseradishperoxidase with the
avidin-biotin method for 1 h (Horseradish Peroxidase Streptavidin,
PK-6100, Vector Laboratories, Burlingame, CA, USA) at room
temperature. Sections were then incubated for 3 min with 0.02%
diaminobenzidine with 0.01% hydrogen peroxide, then dehydrated
and coverslipped with PermountH Mounting Media (SP15-500,
Fisher Scientific, NY, USA).
Quantification
Using an Olympus Confocal Imaging microscope and Olympus
Fluoview FV1000 software, sections from the lumbar spinal cord
were taken with identical acquisition parameters (gain, exposure
time) and analyzed by confocal microscopy to characterize
immunofluorescence (IF). Epifluorescence and bright-field pictures
were taken by a Leica DM4000 microscope equipped with a Leica
DFC350FX and an InfinityX camera for immunofluorescence.
Fos-immunoreactive nuclei were counted when having small,
rounded or ovoid, dark staining, in comparison to control. Laminae
delimitation was performed with a rat spinal cord histo-architecture
template[38],inaccordancewithlumbarsegmentL1/L2/L3ofthe
section. In the present study, c-Fos-immunoreactive cells were
counted as combined laminae I-II, III-IV, V-VI, and VII-VIII,
respectively. Eight 35-mm spinal cord sections over the L1/L2/L3
segment of each animal (n=3) were randomly chosen per animal
per condition to determine total c-Fos number.
The quantification of ATF-3 positive neurons in DRG 12-mm-
thick sections was carried out by counting the number of neurons
with ATF-3 immunoreactive nuclei at 20X magnification, using a
Leica DFC350FX microscope. DRGs corresponding to the lumbar
spinalcordlevelsL1/L2/L3wereselectedasthemainprojectionsites
of primary afferent fibers innervating the femur [39,40]. Counting of
ATF-3 positive cells was performed once in three series, every 36 mm.
This count was expressed as mean number of ATF-3 immunoreac-
tive cells per section (n=24). Sham and cancer animals from 3
independent experiments were used for ATF-3 determination.
Glial staining for GFAP and Iba-1 in the L1/L2/L3 spinal cord
was quantitatively analyzed by optical density with Image J software
version 1.6. Image J was first calibrated with an image from a control
animal using the calibrate function. The settings were then conserved
for all subsequent analyses. Three randomly selected sections of the
spinal cord L1-L3 in each animal (n=3) were analyzed. The optical
densities of nine sections (three sections/animal) were averaged to
provide a mean number for each condition.
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Radiographs wereperformed on dissected bones using a Faxitron
MX-20 (Faxitron, Lincolnshire, IL). Pictures were taken at 26 kV,
exposure time: 10 s; magnification: 2X. Micro-computed tomog-
raphy analyses wereperformed on dissected limbs of tested rats with
a 1072 MicroCT system (Skyscan, Kontich, Belgium). The
parameters were: source: 80 kV, 124 mA; zoom: 20X; pixel size:
14.06 mm; exposure time: 3.0 s; rotation: 0.9u. Bone Volume/Total
Volume(BV/TV)determination:cortical+ trabecular bone volume
(BV) divided by any type of tissue (TV) in the range of 5,626 mm
corresponding to 201 cross sections (volume of interest; VOI),
starting from the growth plate of the distal femur. Trabecular BV/
TV is defined by the trabecular bone volume divided by the TV
from the VOI. Analyses were performed with CT Analyser 1.10.0.1
(Skyscan, Kontich, Belgium).
Magnetic Resonance Imaging and Positron Emission
Tomography
MRI studies were conducted at the Centre d’imagerie mole ´culaire de
Sherbrooke with a 210 mm small-animal 7T scanner (Varian Inc.,
Palo Alto, CA, USA) and a 63 mm volume RF coil. Sprague-
Dawley rats were placed in the supine position in an MRI-
compatible cradle equipped with a homebuilt paw support designed
to position both limbs stably and reproducibly. Animals were
anaesthetized with 3% (induction) and 1.5% (stabilization) isoflur-
ane in oxygen. A feedback-controlled animal warm-air heater
system was used to keep the animal’s body temperature at
physiological levels and the respiration rate was continuously
monitored(SAInstrumentsInc.,StonyBrook,NY,USA).TheMRI
protocol included the acquisition of axial (sagittal) pre-contrast and
10 min post-contrast T1-weighted images, using a gradient echo
sequence with TR: 210 ms, TE: 3.35 ms, flip angle: 30u, matrix:
2566256, FOV: 60660 mm
2, NA: 8 (30 sagittal slices), 1.5 mm
thick. A 600-ml bolus of contrast agent (Gd-DPTA, Magnevist,
Berlex) was injected via the tail vein. Animals were imaged before
and 6, 8, 10, 13, 15 and 18 days post-implantation. To evaluate
tumor invasiveness, a region of interest (ROI), including the whole
bone cortex and medullar channel of the femur, was defined. This
ROI yielded a voxel intensity histogram for both hind paws. The
contralateral maximal voxel intensities were used to fix the
pathological threshold. Every ipsilateral voxel remaining was
colored according to its intensity with a yellow-red scale. Mathlab
Version 7.1 (Mathworks Inc., Natick, Massachusetts, USA) was
used to analyze the data and perform the calculations.
Positron emission tomography was performed using the Lab-
PET4 Sherbrooke with Core Temperature Control. Ring diameter:
162 mm; FOV: 37.5 mm; Cristals: 3072; Spatial resolution:
1.35 mm FWHM FOV; Noise-equivalent counts: 37 kcps at
245 MBq (250–650 keV). Immediately after MRI scans, animals
remained under anesthesia in the same position and the cradle was
transferred to the PET scanner. The collimator was aligned to the
hind knee joints; 9.25 MBq of Na
18F was injected i.v. (200 mla t
500 ml/min). The distribution of the radiotracer was monitored
over 30 min and double-volume sampling was performed for
30 min. Breathing and body temperature of the animal were
monitored at all times throughout the procedure.
Histological analysis and measurement of osteoclast
activity
Twenty-one days after tumor injection, rats were euthanized
and femora were removed. Femurs were fixed in 4% paraformal-
dehyde for 72 hours, decalcified in 10% EDTA (pH 7.4) for 2–3
weeks, and finally embedded in paraffin. Paraffin blocks were cut
in 3- or 5 mm-thick sections with a microtome equipped with a
carbide blade and slices were stained with Harris’ hematoxylin and
eosin to determine cancer cell infiltration and bone destruction.
To identify activated osteoclasts, tartrate-resistant acid phosphate
(TRAP) staining was performed. Using the Leukocyte (TRAP) Kit
(Sigma-Aldrich, St. Louis, Missouri, United States), the slices were
exposed to the substrate for 1 hour and staining was visualized
with a Leica DM4000B (Leica, Toronto, ON, Canada). In total,
3.5 fields were counted at a magnification of 250X for a total
surface of 1 mm
2. Labeled osteoclasts were counted along the
mineralized bone-tumor or the bone-bone marrow interfaces and
4–7 slices were analyzed for each animal, from groups of 4
animals.
Statistical analyses
Von Frey and DWB data were analyzed using a two-way
ANOVA followed by Bonferroni’s post-hoc test and Randall-
Sellitto was analyzed with a Student’s t-test for comparison of
contra- and ipsilateral hind paws for each day. C-Fos, ATF-3 and
Iba1/GFAP count differences were determined with a repeated
measure ANOVA followed by a Bonferroni multiple-comparison
test. Normality was evaluated with Kolmogorov-Smirnov and
Shapiro-Wilks tests. BV/TV graphs were analyzed with a one-way
ANOVA and TRAP counts with a Student’s t-test. P#0.05 was
considered as the level of statistical significance.
Results
Implantation of breast carcinoma cells in the femur
induces touch-evoked and ambulatory pain
In the attempt to mimic clinical bone cancer pain, we per-
formed a local injection of the cells directly in the femur between
the medial epicondyle and the adductor tubercle. The impact of
surgery was minimized by implantation at this anatomical site,
which reduces the chances of patellar ligament or joint damage.
Accordingly, as assessed by von Frey and dynamic weight bearing
(DWB), sham animals showed no signs of mechanical allodynia or
locomotion impairment throughout the behavioral test period
(Figs. 1A, C), even in early days following the surgical procedure
(data not shown). Cancer-bearing male rats inoculated with 30,000
MRMT-1 cells displayed a decreased withdrawal threshold in the
dynamic von Frey test from day 14 (36.762.0 g; p,0.05; Fig. 1A).
After that, allodynia rapidly progressed until day 21, when it was
maximal (23.361.5 g, p,0.001). Cancer cells inoculated in the
right hind paw did not elicit mechanical allodynia on the
contralateral side (Fig. 1A). Concomitantly to allodynia, mechan-
ical hyperalgesia developed progressively in tumor-bearing rats. As
measured with the Randall-Selitto test, a significant difference was
observed between ipsilateral and contralateral paw withdrawal
thresholds from day 18 (30.9610.8 g, p,0.001) to day 21
(25.767.6 g, p,0.01; Fig. 1B). These results demonstrate that
measurable touch-evoked pain behaviors develop after the injec-
tion of carcinoma cells into the femur, as previously demonstrated
with MRMT-1 cell implantation in the tibia [24]. After pain
detection on day 14, subcutaneous administration of morphine
(3 mg/kg) did not reverse mechanical allodynia induced by tumor
progression in cancer-bearing rats (Figure S1).
Limb discomfort was first assessed by static weight-bearing.
From day 15, half of the ipsilateral weight was redistributed to the
contralateral paw (data not shown). In order to evaluate a
representative weight redistribution across the animal’s entire
body, without restraint, we performed DWB assessments. The
kinetics of transfer to the hind paws were similar to those observed
in static bearing, starting around day 12 and increasing until day
Focus on Bone Cancer Pain
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was mainly made upon body parts other than the contralateral
hind paw, such as the tail, bottom abdomen or forepaws. Indeed,
at day 21, approximately 50% of the weight was borne elsewhere
than the hind paws, in comparison to 33% prior to pain onset
(data not shown). Accordingly, the paw surface in contact with the
floor was also significantly affected from day 15, as compared to
the contralateral paw (Fig. 1D). These pain behaviors mirror the
clinical observation of breakthrough pain, which is experienced
after the movement of tumor-bearing limbs in bone cancer
patients.
Neuronal and glial plasticity in cancer-bearing animals
Metastasis proliferation in the rat femur induces neuronal
activation and glial changes throughout afferent fibers projecting
to L1-L3 spinal lumbar segments. Fourteen days following
MRMT-1 cell implantation, immunohistochemical analyses were
performed on spinal cord and DRG tissues to examine the
resulting neurochemical alterations. C-Fos and ATF-3 immediate-
early genes were used to follow spinal and sensory neuronal
activities (Fig. 2 and 3, respectively). First, we observed a repetitive
and scattered c-Fos expression pattern in the ipsilateral spinal horn
of tumor-injected rats (Fig. 2A). At day 14 post-surgery, an intense
increase in the number of c-Fos-immunoreactive neurons was
observed towards deeper laminae V-VI and VII-VIII in spinal
cord segments L1-L3, as compared to sham animals (Figs. 2B, D).
In contrast, C-Fos staining was almost absent in the contralateral
side (Figs 2C, E). As the tumor cells filled the intramedullary space
of the bone, a significant up-regulation of ATF-3 expression also
occurred in sensory neurons of the ipsilateral DRG (Figs 3A, B). At
14 days of cancer development, ATF-3 reactivity was absent in
sham and contralateral sensory neurons (Fig. 3C). Typically,
ipsilateral cancer DRG sections displayed seven times more ATF3-
positive neurons than their corresponding contralateral part or the
sham group (Fig. 3D). As previously observed in sarcoma-injected
animals [11], substance P (SP) and isolectin B4 (IB4) immunore-
activities, labeling peptidergic and non-peptidergic small project-
ing nociceptive fibers, respectively, remained unchanged (data not
shown).
Further, glial involvement was determined with Iba1 and GFAP
markers, labeling microglia and astrocytes, respectively (Fig. 4).
Microglia are recognized as pathology sensors capable of reacting
to neuronal disturbances. Iba1 staining was increased in the
ipsilateral dorsal horn 14 days after cancer cell inoculation of the
femur (Figs. 4A, B). Iba1 fluorescence intensity was increased
by 36% in the ipsilateral dorsal horn in comparison to its
contralateral counterpart (p,0.05) and by 44% when compared
to sham animals (p,0.05; Table 1). The labeling appeared to be
widespread across dorsal horn laminae I-V, with the most pro-
minent increase observed in laminae III-IV (Fig. 4A). Ipsilateral
Figure 1. Evaluation of mechanical sustained pain on a 21-day schedule following the implantation of MRMT-1 cells in rat right
distal femur metaphyse. (A) Allodynia was determined using the von Frey test following tumor implantation. The withdrawal threshold diminishes
progressively from day 11 in response to nociception accommodation in cancer-bearing animals (n=10). The contralateral paw remains unaffected,
as does the sham-treated ipsilateral limb (n=10). (B) Evaluation of hyperalgesia was performed using the Randall-Sellitto test. Results are expressed
as the paw withdrawal threshold (PWT) difference between the ipsi- and contra-lateral hind paws. Significant hyperalgesia was observed at days 18
and 21 (n=10). (C) Quantification of dynamic weight-bearing in the implanted animals, expressed as a percentage of animal weight. A significant
difference in weight distribution on each paw is observable from day 15. (D) Dynamic analysis of the surface of contact between the hind paw and
the sensor presents similar results at day 15, 18 and 21 when the ipsi- and contralateral paws are compared in cancer groups (n=7 in each group).
Data are mean 6 S.E.M, *: p#0.05; **: p#0.01 ***: p#0.001.
doi:10.1371/journal.pone.0013774.g001
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amoeboid-shaped cells that are characteristic of activated micro-
glia (Fig. 4B). Surrounding this intense gliosis zone, processes of
microglial cells were rather ramified and branched outside laminae
IV to VI, more representative of resting microglia, as observed on
the contralateral side (Fig. 4C). There was no statistical difference
in Iba1 labeling between sham animals and the contralateral side
of cancer-bearing rats (Table 1). Normal and reactive astroglia
were also detected 14 days post-surgery in L1-L3 spinal lumbar
segments using GFAP (Fig. 4). Ipsilaterally, cancer-bearing rats
displayed hypertrophic astrocytes characterized by cell body
enlargement and extensive arborization of their distal processes
Figure 2. Expression of c-Fos protein in neurons of the spinal cord of bone cancer-bearing animals 14 days after implantation into
the femur. (A) Photomicrograph of an L3 section of the spinal cord of a tumor-bearing rat depicting c-Fos protein’s global expression profile. (B–C)
High magnification of the ipsilateral and contralateral dorsal horn laminae V-VI, respectively. Black arrowheads point to c-Fos proteins only in the
ipsilateral limb. (D–E) Histogram representations of Fos-LI neurons per laminae in cancer animals for ipsilateral and contralateral sides, respectively.
Data are mean 6 S.E.M. number of Fos-LI neurons in the different spinal cord segments for sham and cancer rats (Scale bars, A: 200 mm; B,C: 30 mm;
n=23 sections from 3 rats/group; *: p#0.05; ***: p#0.001).
doi:10.1371/journal.pone.0013774.g002
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appeared in their basal, inactivated morphological state in sham
animals and on the contralateral side (Fig. 4E). This astrogliosis
observed at the immunohistological level was, however, not
reflected in the quantification of GFAP staining (Table 1).
Interestingly, the central canal area (lamina X) was highly labeled
in lumbar spinal cord segments that receive primary afferent input
from the affected femoral bone (Fig. 4F). These results indicate
that both neuronal and glial cells were activated ipsilaterally
during bone cancer development.
Characterization of bone remodeling by faxitron and
microcomputed tomodensitometry (mCT)
X-rays were taken to evaluate the impact of cancer proliferation
on solid structures of the bone (Fig. 5A). The first acquisitions
showed a progressively degrading metaphysis throughout 21 days
of observation. Osteopenia gradually increased from day 14 and
the cortical line was blurred from day 18 (white arrowhead). At
day 21, a bulge shape was forming due to irregular deposition of
bone matrix by osteoblasts. At that time, some animals presented a
fragile structure characteristic of an A3 comminuted metaphyseal
fracture. Micro X-ray computed tomography (mCT) was per-
formed to provide insight into the loss in bone density and
organization and to record trabecular bone morphometric para-
meters (modelization extrusion; Fig. 5B), as compared between
sham and cancer-bearing rats. Scans showed a rough aspect from
day 14 and severe progressive bone loss was observed at days 18
and 21. The dental amalgam was still in place and unaffected in
the 21-day implanted femur. A global structural degradation was
demonstrated by a decreasing volume ratio of whole bone
structure (BV) over total volume of tissue (TV) in the region of
interest (whole bone BV/TV; 65.8% and 75.3% decrease at days
14 and 21, p,0.01; Fig. 5C). More precisely, the level of
trabecular remodeling, determined by the ratio of trabecular BV
over TV, was significantly lower in cancer-bearing animals
compared to shams at day 14 (74.8% decrease), 18 (93.9%) and
21 (88.4%) (p,0.05 and 0.01; Fig. 5D). By extrapolation, cortical
bone degradation thus accounted for a large proportion of the
degradation. Trabecular architecture weakening was also exposed
by an increasing trend in trabecular pattern factor (+78.7% on day
18 (not shown)), representative of lower connectivity between bone
fragments within the medullary canal. This altered architecture of
the spongy bone may be attributable to tumoral and osteoclas-
tic activity as well as to compensatory bone remodeling. The
trabecular number, an indicator of bone density within the region
of interest (ROI), was also drastically decreased at day 21 (80.1%
of sham group, p,0.05; not shown). Finally, these results support
the osteolytic character of the tumor in the femur of male rats as
exposed on X-rays.
Monitoring tumor proliferation and bone invasion by
PET/MRI
MRI offers an excellent soft-tissue contrast [41] and information
on tissue perfusion and microvessel permeability. Na
18F PET
provides an assessment of bone integrity and turnover. When com-
bined, these two imaging modalities yield a more complete picture
of pathological bone status. Sagittal gadolinium-enhanced T1-
weighted MR images of the tumor-implanted rats were acquired at
Figure 3. ATF-3 immunoreactivity in DRG neurons of bone cancer-bearing animals 14 days after implantation into the femur.
(A) Primary ispilateral L3 DRG sub-populations of sensory neurons showing ATF-3-IR-positive neurons marked by dark labeled nuclei with DAB
staining (black arrowheads). (B) ATF-3 immunofluorescence labeling was performed to confirm the presence of Fos reactivity (white arrowheads).
(C) Immunohistochemistry for ATF3 in the corresponding contralateral DRG. (D) Histogram representation of ATF-3 positive neurons per section in
cancer and sham animals. Data are mean 6 S.E.M. number of ATF3-LI neurons (n=24 sections from 3 rats/group; ***: p#0.001; scale bar: 50 mm).
doi:10.1371/journal.pone.0013774.g003
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selected region of interest of the sagittal images using thresholds
established from a signal intensity histogram highlights the time-
dependent nature of tumor progression (Fig. 6B). The intact femur
at day 0 presented a regular cortical line and even perfusion of the
bone marrow by contrast agent Gd-DTPA. At day 18, diffuse
hyperintense medullary infiltration was observed throughout the
diaphysis, corresponding to the tumor’s spread (white arrowheads).
The femoral shaft acquired a rougher aspect, with a fading cortical
line proximal to the metaphysis. The bulge shape of the femo-
ral head was consistent with the X-ray observations (Fig. 5A).
Contrast enhancement was also observed in the surroundings of
the bone, indicative of possible periosteal inflammation and edema
(Figs. 6A, B; blue arrowheads). The medullary cavity was gradually
invaded and the presence of hypointense regions was emphasized,
characteristic of necrotic islets and amalgam artifacts at the site of
injection (Fig. 6B; day 18, black arrowhead). Notably, the tumor
was detected as early as day 8 post-implantation, thus 6 days prior
to pain onset, as measured in the dynamic von Frey test (Fig. 1A).
Na
18F PET images were co-registered to MR images for
morphological reference (Fig. 6C). Fluoride ions are chemisorbed
on bone hydroxyapatite crystals, providing insights on bone
metabolism and structure and instantly reflecting increased uptake
in the surroundings of bone metastases [42]. This procedure is
Figure 4. Microglia and GFAP staining in dorsal horn of the L3 spinal cord of rats at day 14 post-surgery. (A) An increase in Iba1
labeling is observable in the ipsilateral dorsal horn. (B) At high magnification (insert), glial cells are morphologically characterized by an increase in
the length of distal processes. (C) The carcinoma does not induce alterations in the contralateral spinal cord microglial pattern. (D) The distribution is
relatively similar in the ipsilateral superficial dorsal horn; however, astrocyte cell bodies are hypertrophied (insert). (E) On the contralateral side,
astrocytes are distributed homogenously throughout the superficial laminae. (E) An increase in GFAP-IR is observed around the central canal in
laminae X. Scale bars A,C,D,E: 50 mm; D insert: 15 mm; B: 30 mm; F: 100 mm).
doi:10.1371/journal.pone.0013774.g004
Table 1. Quantification of glial activity at the lumbar level of
spinal cord in bone cancer after 14 days.
Iba1 GFAP
Ipsi Contra Ipsi Contra
Cancer 19.0464.96 12.2462.18
# 48.0263.61 46.9764.20
Sham 10.8361.97* 10.2760.60 45.8162.62 41.3662.35
Fluorescence immunohistochemistry was performed and quantified in dorsal
spinal cord (L1-L3) of cancer-bearing and sham rats (n=8). IBa1
immunolabeling of microglia showed a significant increase in fluorescence
intensity between ipsilateral and contralateral sides (#;p ,0.05) and between
carcinoma-implanted animals and sham-group ipsilateral sides (*; p,0.05).
GFAP immunostaining of astrocytes did not reveal any significant difference in
fluorescence intensity thresholds between groups.
doi:10.1371/journal.pone.0013774.t001
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PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13774Figure 5. Radiological images of bone cancer-bearing rat femurs. (A) Faxitron anteroposterior radiographs of sham-operated and cancerous
femur distal heads after 14, 18 and 21 days. At day 14, osteopenia is observed in the medullar canal of the bone while cortical integrity is maintained.
At 18 days, the cortical line is blurred, characteristic of severe supracondylar osteopenia (arrowhead). Cortical bone integrity is partially compromised,
contributing to the appearance of fracture. Twenty-one days after implantation, the bone shape is irregular due to anarchic matrix redeposition. An
A3 metaphyseal complex fracture is present following such severe bone loss, affecting bone shape. (B) Microcomputed tomodensitometry of sham-
operated and cancer-bearing rat femurs. The shaft represents cortical mineralized bone, while the extrusion represents trabecular bone. Sham femurs
show intact structure and high cortical and trabecular densities. After 14 days, the metaphyseal cortical bone surface becomes irregular and porous,
while the epiphysis remains intact above the growth plate. Trabecular reconstruction at day 18 reveals extensive bone loss, while the cortical
architecture weakens. At day 21, the bone integrity is seriously compromised and marked by signs of potential fracture. (C) Bone modeling is
quantified by the measurement of bone volume/tissue volume ratios, expressed in %. Throughout the entire bone structure, proportional bone
content is significantly modified from day 14, with a greater decrease in bone percentage at day 21. (D) When the analysis is limited to the cancellous
bone only, the same modifications, this time in trabecular architecture, are observed. (*: p#0.05; **: p#0.01; n=4–5).
doi:10.1371/journal.pone.0013774.g005
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aggressiveness at the time of the scan, a methodology that would
otherwise require multiple sessions of CT scans to detect a path-
ological evolution. Day 18 images displayed a photopenic lesion at
the distal metaphysis in comparison to the contralateral side
(Fig. 6C; orange arrowheads). Moreover, the ipsilateral border of
the metaphysis/diaphysis region was marked by intense sclerotic
bone activity (white arrowhead). The latter phenomenon is
characteristic of a predominantly lytic pattern in a mixed bone
tumor, as encountered in the clinic [43,44].
Histological overview of bone remodeling during tumor
proliferation
The severity of the cancer model was also confirmed by classic
histological approaches used to support non-invasive imaging data.
The H&E staining enabled us to contrast healthy structures in the
sham-operated group (Figs. 7A, B) after 21 days to cancer-bearing
rats (Figs. 7C, D). Heavy signs of degradation, depicting an
imbalance in osteo-clast/blast homeostasis, were identified in the
trabecular spongy bone and ultimately replaced by necrotic
clusters of tumor cells. Hematopoietic cells from the bone marrow
were superseded by carcinoma cells. The cortical line was slender
and irregular. However, we noted that despite the aggressiveness
of the MRMT-1 cells, the calcified cartilage was unaffected and
acted as a barrier to femoral epiphysis invasion (arrows). The
chaotic architecture of the femur metaphysis structure in cancer-
bearing animals was indicative of substantial lytic activity. We then
evaluated the number of active multi-nucleated osteoclasts per
surface, as measured using the Tartrate Resistant Acid Phospha-
tase staining protocol, which revealed brownish cytoplasmic
staining indicative of osteoclasts (Figs. 7E, F, arrowheads). The
number of osteoclasts per square millimeter was three times
greater in the cancer group than in the sham-operated group
(Fig 7G; p,0.001). This massive lytic activity accounted for the
severe osteopenia observed, which increased the risk of fracture
within 21 days of experimentation.
Discussion
Bone cancer pain is a complex clinical syndrome; the
mechanism remains to be elucidated. Advanced breast cancer
often evolves towards bone dissemination and severe pain. Pre-
clinical animal pain models mimicking relevant clinical observa-
Figure 6. Medical imaging of bone tumor using MRI and PET.( A) Contrast-enhanced (Gd-DTPA) T1-weighted magnetic resonance (MR)
images of a rat coping with femoral bone cancer. Bone images of the proximal tibia (T) and whole femur (F) show dispersion of the contrast agent in
normal (top) and cancerous (Day 18; bottom) bones in a sagittal plane (n=8). Cortical bone shows lower intensity (black), while soft-tissue areas are
in shades of gray. Tumor proliferation affects the regular cortical line at day 18. Hyperintense areas within the medullary channel represent the tumor-
affected distal part of the femur (white arrowheads). Enhanced areas outside the bone are characteristic of inflammation and edema (blue
arrowhead). (B) Sagittal plane close-ups of the distal femur at different stages of tumor progression. Images are superimposed to artificial colors
corresponding to voxel intensities and are indicative of tumor proliferation in the medullary channel. Tumor is detected at day 8 and its intensity and
surface increase consistently throughout the experiment. Blue and black arrowheads label periosteal inflammation and necrotic clusters, respectively.
(C) Sodium
18fluoride positron emission tomography scans of contralateral and ipsilateral cancer-bearing bones at day 18 post-cancer cell
inoculation. The positioning remains the same between MRI and PET scans. Contralateral bone shows a high
18fluoride intake at the trabecular bone
level, while the shaft of the femur remains lightly labeled. In contrast, the cancer-affected bone displays a markedly decreased signal at the distal
extremity (orange arrowheads), while a high intensity signal is observable at the level corresponding to the proximal edge of the tumor area (white
arrowhead). This is representative of substantial bone remodeling (n=3).
doi:10.1371/journal.pone.0013774.g006
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PLoS ONE | www.plosone.org 10 October 2010 | Volume 5 | Issue 10 | e13774Figure 7. Hematoxylin & eosin coloration and quantification of TRAP staining in the rat distal femur at day 21 post-surgery. (A–B)
Photomicrograph representative of the sham surgery group showing healthy bone structures (BM = Bone Marrow; SB = Spongy Bone). (C–D) Cancer-
implanted bone illustrating an unstructured architecture. Note that the cartilage is still unaffected (arrows). Hematopoietic cells from the bone marrow
areentirely replacedbyproliferatingMRMT-1cells(Tu).Necroticclusters(NC) appearinearlyareasofproliferation. Cancellousboneissparselydeposited
in a mosaic pattern, yielding fragile and disorganized bone. Larger lacunae and immature bone are indications of compensatory reconstruction. (E–F)
Photomicrographs of trabecular bone stained with the TRAP coloration technique. Multinucleated active osteoclasts, bordering the hydroxyapatite
matrix, are stained in brown-red (black arrows) in sham (E) and cancer-bearing (F) rats. (G) The number of differentiated osteoclasts per mm
2 is three
times greater in cancer rats than in sham animals, explaining the accelerated degradation of bone structure. ***: p#0.001 (n=12 for sham andn=20 for
the cancer group). Scale bars A,C: 1 mm; B,D,E,F: 90 mm.
doi:10.1371/journal.pone.0013774.g007
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generation of pain and facilitate the development of preventative
and palliative therapies.
A new model of bone cancer pain
Based on clinical observations, the femur is the most frequent
site of breast metastases in long bones [28]. It is also the second
most common site (35% of cases) of pathological fracture induced
by bone cancer [45]. To this day, disseminating breast-to-bone
models, although relevant, lead to high variability in the targeted
sites, rendering study of the mechanisms of bone cancer pain
genesis and maintenance difficult to isolate [32,33,46]. On the
other hand, models using local bone implantation to mimic cancer
pain often use cell lines from primary cancers such as fibrosarcoma
[15,30,47,48,49,50]. Bone metastases secondary to breast cancers
are more likely to induce chronic pain. Therefore, in the present
study, we developed a model of bone cancer pain induced by the
femoral invasion of breast carcinoma in the male rat. We
cautiously chose to use male rats to avoid hormonal variations
that are well-known to influence pain response [51,52] and
considering the fact that we demonstrated that MRMT-1 cells
express estrogen receptors. We felt that it was preferable to first
pursue our investigation on males in order to limit those variations
and compare the evolution of pain and the progression of bone
remodeling to other reported cancer pain models. Indeed,
MRMT-1 cells have been abundantly used in the past to assess
bone cancer pain following breast cancer cell inoculation in either
males [53,54,55,56,57] or females [9,20,21,24,58,59]. The
behavioral, immunohistochemical, pathological and medical
imaging approaches used to characterize, provide evidence that
suggests a resemblance to the chronic and invasive pathology that
develops in humans [60]. Importantly, we opted to minimize
impairment due to the implantation step. Thus, the tumor is the
exclusive source of pain and we avoid confounding variables (e.g.,
early inflammation, transient pain, locomotion discomfort attrib-
utable to surgery). Recent models of bone cancer pain, targeting
the femurs in mice, consisted in arthrotomia, displacement of the
patellar ligament and knee joint alteration [24,30]. Affecting the
subchondral bone can expose nociceptors in regions susceptible to
biomechanical forces, thus amplifying weight-bearing pain [61].
The implantation approach suggested here does not result in pain
or extraosseous inflammation.
A relevant evaluation of behavioral pain
Breakthrough pain episodes frequently occur as the tumor
infiltrates the bone matrix. These transitory episodes of extreme
pain are evoked by non-noxious movement or mechanical loading
of the tumor-affected bone. Breakthrough pain at rest (spontane-
ous) and during ambulation (volitional) is the first presenting
characteristic of patients consulting a physician for metastatic
disease, is highly prevalent in bone cancer patient cohorts, and is
also an indicator of fracture risk [62,63,64,65]. However, stimulus-
evoked withdrawal thresholds remain the mainstay of pain
evaluation. While we evaluated the consistency of the development
of touch-evoked pain in previous bone cancer studies [13,24], we
investigated volitional pain to maintain clinical relevance. Static
weight bearing has been used to determine the difference between
cancer-bearing and healthy paws. However, the animal is
restrained and stressed, masking information that could potentially
be used to describe volitional pain. Consequently, we tested a
dynamic weight-bearing system to monitor weight distribution
during free ambulation in an open enclosure. The weight borne by
any standpoint of the animal and the surface of contact were
measured over an extended period of observation by floor captors.
Therefore, we gained a greater appreciation of volitional pain,
supported by the fact that our animals showed no discomfort
following the implantation procedure. Additionally, we demon-
strated that weight was redistributed entirely upon standpoints
other than the contralateral hind paw, such as the tail and front
paws. Thus, analgesics proven efficient in reversing weight-bearing
to initial values in a static apparatus might not reflect reality. To
avoid bias in evaluation of analgesic potency, quadrupeds should
be tested in a natural ambulation position, just as humans would
be tested in a standing posture. Therefore the model proposed
here should be more persuasive in the attempt to evaluate the
effect of analgesic treatments on volitional pain, ultimately
resulting in more successful transfer of animal models to the clinic
[64].
Neurochemical changes occurring in bone cancer pain.
Bone cancer generates a profound reorganization in the DRG and
spinal cord at both neuronal and glial levels. As previously
observed in rat sensory and motor neurons following spinal and
sciatic nerve injury [66,67] and recently in mouse bone cancer
models [15,68,69,70], ATF-3 was shown to be up-regulated in
DRG neuron somas 14 days after tumor implantation. This
neuronal hyperactivity accompanying hyperalgesia and allodynia
is also detected in the spinal cord, reflecting the central sensi-
tization phenomena frequently observed in chronic pain states. In
the present model, c-Fos-expressing neurons were significantly
increased in deeper laminae V-VIII of the spinal cord following
MRMT-1 carcinoma cell inoculation. However, in a previous
study, sarcoma-induced c-Fos activation was observed in super-
ficial layers I-II of the dorsal spinal horn [30,71]. In neuropathic
pain, non-nociceptive Ab fibers are stimulated, increasing neuro-
nal firing towards lamina V-VI of the spinal cord [72]. Therefore,
Ab fiber over-activation may be related to acidic tumor environ-
ment or nerve compression, thus contributing to c-Fos activation
in deep layers. In human, the quality of bone cancer pain is
marked by substantial heterogeneity, either due to the cancer or
resulting from the alteration of distinct bone structures. These
discrepancies in c-Fos expression may therefore reflect sensory
inputs conducted by unmyelinated or myelinated fibers innervating
either the bone marrow, the mineralized bone, or the periosteum.
Glial cell phenotypic changes were also marked by astrocyte
hypertrophy and distal processes of increased length, in both the
dorsal and ventral ipsilateral lumbar L1-L3 spinal cord. Recruit-
ment of activated astrocytes may contribute to the initiation and
maintenance of persistent cancer and neuropathic pain states, as
previously reported [73,74]. Interestingly, GFAP staining was
intense in lamina X, a region known to relay visceral information.
Tumor invasion of the marrow and the sinusoid walls of the distal
metaphysis is likely to sensitize nerve fibers at this site and
stimulate central astrocyte recruitment. Using a neurotropic viral
approach, Denes and colleagues [75] infected bone marrow and
demonstrated retrograde neuronal labeling of the central gray
matter in lamina X of lumbar segments after 4 days. This is in line
with a high prevalence of referred visceral pain in the cancer
population. In the present model, we also found a substantial
increase in microglia in the ipsilateral dorsal horn, concurrent to
the observations made by Zhang and colleagues [27] in the rat but
in opposition to the unchanged staining previously obtained with
OX-42 in mice [30,71]. Microglial activation was shown to peak
after 1 week of injury and to decline over several weeks thereafter
[76]. However, most of the bone cancer research groups per-
formed analyses of duration ranging from 19 to 21 days. In our
case, at day 14, we were able to observe hypertrophied microglial
bodies in laminae V and a large number in other laminae, factors
that represent a post-active or latent state in response to an insult.
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astrocytes in this bone cancer-induced pain model awaits further
investigation.
Detection of early bone metastases by a clinical imaging
approach
Most of the clinical problems associated with metastatic bone
diseases are a result of tumor-induced dysregulation of abnormal
bone turnover. The development of non-invasive imaging
modalities (PET/MRI) providing early diagnosis of bone remod-
eling and allowing physicians to monitor the therapeutic response
has provided advantages beyond those of plain film radiographs.
Recent human studies also showed that Na
18F PET is more
sensitive than
99Tc radionuclide bone scan in detecting metastases.
In fact, Na
18F PET allows physicians to detect all osteolytic
metastases, while radionucleide bone scan detects only 49.3% of
metastases [77]. Furthermore, a recent study revealed that MRI is
superior to CT in detecting the presence and extent of bone
marrow metastases [78]. CT could only identify 17% of these
tumors, while MRI could reveal the presence of 83%. This is of
crucial importance when choosing the appropriate treatment, as
24% of the patients saw their treatment modified after an MRI, as
compared to the treatment prescribed after a prior CT scan [78].
Accordingly, PET/MRI holds the best potential to assess the
potency or efficacy of tumor-suppressing treatments at preclinical
and clinical levels [79].
Bone resorption and tumor growth are the most important
aspects of pain onset [8,68]. Therapeutic validity would therefore
be supported by an appropriate correlation between tumor
development and activity profiles versus pain intensity. Our results
reveal timely and reproducible detection and monitoring of bone
tumor growth in the same animal by MR imaging. This proves
useful, considering that clinical and preclinical PET/CT analyses
are limited by the amount of ionizing radiation applied to the
subject, which can potentially reduce the frequency of follow-up
sessions. Advantageously, MRI techniques developed for small
animals are often adapted for use in humans. Further, our MRI
studies allowed us to detect the tumor at day 8 post MRMT-1 cell
inoculation, prior to pain onset in every case. Thus, the
mechanical compression of bone tissues and the algogenic
substances released by the bone environment and tumor at day
8 are not sufficient to exacerbate nociceptors and stimulate
abnormal neuronal firing. Thus, detecting bone metastases before
symptomatic pain would support a prophylactic approach in
metastatic disease management. PET images showed decreased
18F accumulation in the area affected by the tumor after
administration of Na
18F. This confirms the high lytic character
of the mammary carcinoma, since the high affinity of
18F for bone
hydroxyapatite normally results in large signal intensities in the
normal trabecular bone. In contrast, accumulation of
18F in the
region surrounding the tumor was observed, indicative of active
bone turnover. Increased osteoblastic activity induced in an
attempt to compensate for the lytic activity of the tumor could
account for the enhanced signal observed [7]. Indeed, a high
number of osteoclasts were detected in the regions adjacent to the
tumor in histological sections, and anarchic bone turnover was
also seen in the femur metaphysis in cancer-bearing animals.
Altogether, these observations show that metastases-induced loss of
integrity in the tumor-bearing bone contributes to promoting
movement-evoked breakthrough pain in cancer patients. Indeed,
prevention of bone metabolism imbalance, through bisphospho-
nates therapy for example [18], in combination with early
treatment of tumor progression and pain development – as well
as their timely evolution – could be monitored using PET and
MRI co-registration technology.
Aiming for osteoclastogenesis
Breast cancer usually displays a dominant lytic profile when it
metastasizes to the bone [80]. This fact is also observed in our
cancer model, as determined by mCT analyses that reveal a
striking decrease in trabecular bone content. This is in accordance
with the dense and slurry vascularization present within the
trabeculae, rendering the bone ideal for embolus nesting. Tumor
expanded beyond the limit of the compact cortical bone, de-
monstrating the aggressiveness of the MRMT-1 cells in infiltrating
and degrading the bone matrix. Extra-femoral spicules, charac-
teristic of compensative bone formation were detected, consistent
with other studies [7]. The trabecular pattern, an indicator of
connectivity within the trabecular architecture, was strongly
increased in cancer-bearing bones. In humans, biopsies are used
for trabecular architecture evaluation [81,82]. Clinically, a higher
trabecular pattern factor is correlated with a higher risk of fracture
[83]. Close monitoring of these parameters and manifestations is
important to minimize pain.
Several observations from the present study emphasize the
crucial role of osteoclasts in cancer-induced bone loss and in the
etiology of bone cancer pain. Histological analyses demonstrated
that tumor progression had a dramatic effect on osteoclast activity.
Indeed, TRAP-positive multinucleated cells tripled in number and
displayed typical hypertrophic bodies. This explains, in part, the
decreased bone volume observed using the mCT and the decreased
18F uptake in the most affected areas of the bone. The tumor
releases osteoclast maturation factors or stimulates osteoblast
secretion of RANKL and down-regulation of osteoprotegerin,
resulting in dominant resorptive activity [9,84,85]. In addition to
prostaglandins and other factors released by the tumor, bone
resorption results in the release of protons that will stimulate
nociceptors. The number of osteoclasts is therefore an indicator of
potential bone pain onset and should be screened in every bone
cancer model.
Conclusion
While pain occurs at any time point during the course of the
disease, in general, the more advanced the cancer, the more likely it
is thatthepatientwill experienceintractable pain.Thedevelopment
of treatments to reduce the incidence of bone metastases is therefore
of great clinical significance to improve the quality of life of bone
cancer-bearing patients. Medical imaging at the site of the tumor in
combination with pain assessment is the key to determine the
efficacy of cancer treatments. Indeed, the evaluation of tumor
progression could elucidatetheonsetofpain.Withrecentreportson
the adverse effects of analgesic therapies on bone homeostasis [15],
skeletal structure must be monitored during follow-up, in parallel
with chronic pain management. The methods we propose in this
animal model are based on clinical multimodal approaches and are
intended to optimize the research and development of therapeutic
strategies for bone cancer pain.
Supporting Information
Figure S1 Evaluation of the effect of subcutaneous morphine on
bone cancer pain induced by MRMT-1 breast carcinoma
inoculation. Mechanical allodynia was evaluated following acute
administration of 3 mg/kg of morphine sulfate (MS), starting at
day 6. The paw withdrawal threshold (PWT) was evaluated 30
minutes after morphine injection. After pain detection on day 14,
repeated morphine treatments did not induce any significant
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treated tumor-bearing rats. Note that subcutaneous administration
of morphine was antinociceptive at day 6, just before cancer-
induced pain (** p,0.01; n=7).
Found at: doi:10.1371/journal.pone.0013774.s001 (0.06 MB TIF)
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